A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

A breast cancer vaccine could be closer to reality, according to Cleveland Clinic, as its researchers have announced some encouraging results. Researchers and doctors weigh in.

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Immunology is the study of the immune system and its defense mechanisms, and immuno-oncology is when cancer patients are ...

Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...